Should You Buy Mirum Pharmaceuticals Inc (MIRM) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
102.920
1 Day change
2.05%
52 Week Range
103.810
Analysis Updated At
2026/01/26
Mirum Pharmaceuticals Inc (MIRM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong growth potential driven by its pipeline, recent acquisitions, and analyst confidence, making it a solid choice for long-term growth.
Technical Analysis
The technical indicators for MIRM are bullish. The MACD is positive and contracting, RSI is in the neutral zone at 72.252, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 95.834) with a pivot at 90.02, suggesting potential upward movement.
Options Data
Neutral
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
6
Buy
10
Positive Catalysts
Analysts have consistently raised price targets, with the latest targets ranging from $95 to $140, citing strong pipeline developments and acquisitions.
Revenue increased by 47.17% YoY in Q3 2025, showcasing strong growth.
The company has a robust pipeline with pivotal readouts expected in 2026, driving confidence in its future performance.
Recent acquisitions (e.g., Bluejay) add promising assets and synergies to the portfolio.
Neutral/Negative Catalysts
Net income dropped significantly by -120.41% YoY, and EPS declined by -116.67% YoY, indicating profitability challenges.
No significant insider or hedge fund trading trends, suggesting a lack of strong institutional backing in recent months.
Financial Performance
In Q3 2025, Mirum Pharmaceuticals reported a 47.17% YoY revenue increase to $133.01M, driven by strong sales growth. However, net income dropped to $2.91M (-120.41% YoY), and EPS fell to $0.05 (-116.67% YoY), reflecting profitability challenges. Gross margin improved to 80.8%, up 4.96% YoY, indicating operational efficiency gains.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts are highly optimistic about MIRM, with multiple firms raising price targets recently. Evercore ISI raised the target to $101, Citizens to $140, and H.C. Wainwright to $102. Analysts highlight the company's strong pipeline, acquisitions, and growth potential as key drivers of their positive outlook.
Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 102.33 USD with a low forecast of 81 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 102.33 USD with a low forecast of 81 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 100.850
Low
81
Averages
102.33
High
140
Current: 100.850
Low
81
Averages
102.33
High
140
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$102 -> $130
AI Analysis
2026-01-26
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$102 -> $130
AI Analysis
2026-01-26
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Mirum Pharmaceuticals to $130 from $102 and keeps a Buy rating on the shares. The company's 2026 is a pivotal year for volixibat as clinical evaluation progresses in two chronic immune-mediated cholestatic liver diseases, the analyst tells investors in a research note. The firm says colixibat could launch as early as the first half of 2027.
Evercore ISI
Outperform
maintain
$94 -> $101
2026-01-20
Reason
Evercore ISI
Price Target
$94 -> $101
2026-01-20
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Mirum Pharmaceuticals to $101 from $94 and keeps an Outperform rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MIRM
